Ascent Group LLC Buys 51 Shares of United Therapeutics Corporation $UTHR

Ascent Group LLC boosted its stake in United Therapeutics Corporation (NASDAQ:UTHR) by 7.6% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 718 shares of the biotechnology company’s stock after acquiring an additional 51 shares during the period. Ascent Group LLC’s holdings in United Therapeutics were worth $221,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. SVB Wealth LLC bought a new stake in United Therapeutics in the first quarter valued at $32,000. Sound Income Strategies LLC bought a new stake in United Therapeutics in the first quarter valued at $49,000. State of Wyoming bought a new stake in United Therapeutics in the fourth quarter valued at $62,000. Brooklyn Investment Group boosted its holdings in United Therapeutics by 103.2% in the first quarter. Brooklyn Investment Group now owns 193 shares of the biotechnology company’s stock valued at $59,000 after acquiring an additional 98 shares in the last quarter. Finally, WPG Advisers LLC bought a new stake in United Therapeutics in the first quarter valued at $60,000. Institutional investors own 94.08% of the company’s stock.

Insiders Place Their Bets

In other news, CEO Martine A. Rothblatt sold 8,000 shares of the company’s stock in a transaction dated Tuesday, September 9th. The shares were sold at an average price of $398.55, for a total transaction of $3,188,400.00. Following the completion of the sale, the chief executive officer owned 130 shares of the company’s stock, valued at $51,811.50. This represents a 98.40% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, COO Michael Benkowitz sold 22,500 shares of the company’s stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $417.64, for a total transaction of $9,396,900.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 128,816 shares of company stock valued at $45,836,113. 10.30% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

UTHR has been the topic of a number of research reports. Bank of America boosted their target price on shares of United Therapeutics from $314.00 to $463.00 and gave the company a “neutral” rating in a report on Tuesday, September 2nd. Cantor Fitzgerald boosted their target price on shares of United Therapeutics from $405.00 to $525.00 and gave the company an “overweight” rating in a report on Wednesday. Oppenheimer boosted their target price on shares of United Therapeutics from $510.00 to $575.00 and gave the company an “outperform” rating in a report on Friday, September 5th. HC Wainwright boosted their target price on shares of United Therapeutics from $400.00 to $500.00 and gave the company a “buy” rating in a report on Friday, September 5th. Finally, Morgan Stanley dropped their price target on shares of United Therapeutics from $348.00 to $328.00 and set an “equal weight” rating on the stock in a research note on Thursday, July 10th. Nine equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $438.85.

United Therapeutics Stock Performance

Shares of NASDAQ:UTHR opened at $405.02 on Friday. United Therapeutics Corporation has a fifty-two week low of $266.98 and a fifty-two week high of $436.95. The business has a 50-day simple moving average of $318.53 and a two-hundred day simple moving average of $307.56. The firm has a market cap of $18.27 billion, a price-to-earnings ratio of 15.81, a price-to-earnings-growth ratio of 6.17 and a beta of 0.62.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share for the quarter, missing analysts’ consensus estimates of $6.80 by ($0.39). United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%.The business had revenue of $798.60 million during the quarter, compared to analysts’ expectations of $802.13 million. During the same period last year, the firm posted $5.85 EPS. United Therapeutics’s quarterly revenue was up 11.7% compared to the same quarter last year. As a group, research analysts predict that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.